AstraZeneca PLC (AZN)
77.20
-0.41
(-0.53%)
USD |
NASDAQ |
May 10, 16:00
77.20
0.00 (0.00%)
After-Hours: 20:00
AstraZeneca Accounts Receivable (Quarterly): 11.07B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 11.07B |
December 31, 2023 | 8.407B |
September 30, 2023 | 11.30B |
June 30, 2023 | 11.09B |
March 31, 2023 | 10.29B |
December 31, 2022 | 7.212B |
September 30, 2022 | 9.336B |
June 30, 2022 | 8.908B |
March 31, 2022 | 8.683B |
December 31, 2021 | 6.031B |
September 30, 2021 | 8.258B |
June 30, 2021 | 6.356B |
March 31, 2021 | 6.281B |
December 31, 2020 | 3.806B |
September 30, 2020 | 5.668B |
June 30, 2020 | 5.024B |
March 31, 2020 | 5.08B |
December 31, 2019 | 3.585B |
September 30, 2019 | 5.279B |
June 30, 2019 | 5.319B |
March 31, 2019 | 5.289B |
December 31, 2018 | 2.995B |
September 30, 2018 | 5.509B |
June 30, 2018 | 5.257B |
March 31, 2018 | 5.444B |
Date | Value |
---|---|
December 31, 2017 | 2.802B |
September 30, 2017 | 4.54B |
June 30, 2017 | 4.348B |
March 31, 2017 | 4.686B |
December 31, 2016 | 2.583B |
September 30, 2016 | 5.449B |
June 30, 2016 | 5.619B |
March 31, 2016 | 5.866B |
December 31, 2015 | 4.633B |
September 30, 2015 | 5.876B |
June 30, 2015 | 6.615B |
March 31, 2015 | 6.704B |
December 31, 2014 | 4.762B |
September 30, 2014 | 6.809B |
June 30, 2014 | 7.817B |
March 31, 2014 | 8.579B |
December 31, 2013 | 5.514B |
September 30, 2013 | 7.294B |
June 30, 2013 | 7.268B |
March 31, 2013 | 7.52B |
December 31, 2012 | 5.696B |
September 30, 2012 | 8.001B |
June 30, 2012 | 7.462B |
March 31, 2012 | 8.511B |
December 31, 2011 | 6.63B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
3.585B
Minimum
Dec 2019
11.30B
Maximum
Sep 2023
7.349B
Average
6.784B
Median
Accounts Receivable (Quarterly) Benchmarks
GSK PLC | 8.624B |
Amgen Inc | 6.776B |
Sanofi SA | -- |
Viking Therapeutics Inc | -- |
Fusion Pharmaceuticals Inc | 0.007M |